How big is the bronchodilators market?

The global bronchodilators market size was estimated at USD 22.19 billion in 2022 and is expected to reach USD 22.77 billion in 2023.

What is the bronchodilators market growth?

The global bronchodilators market is expected to grow at a compound annual growth rate of 3.29% from 2023 to 2030 to reach USD 28.75 billion by 2030.

Which segment accounted for the largest bronchodilators market share?

Beta-adrenergic bronchodilators dominated the bronchodilators market with a share of 41.15% in 2022. This class of medications are beta-2 agonists and target smooth muscle cell receptors for dilation of airways. Major products in the short acting category include levalbuterol (Xopenex HFA), albuterol (Proair HFA, Proventil HFA, AccuNeb, Ventolin H FA), and epinephrine injection.

Who are the key players in bronchodilators market?

Some key players operating in the bronchodilators market include F. Hoffmann-La Roche Ltd, GSK plc., Johnson & Johnson Services, Inc., AstraZeneca, Siemens Healthcare GmbH, Abbott, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Quest Diagnostics Incorporated., and FOUNDATION MEDICINE, INC.

What are the factors driving the bronchodilators market?

Key factors that are driving the market growth include growing geriatric population, increasing prevalence of lung diseases, rising awareness about lung diseases treatment aided with escalating R&D efforts by key players operating in the market.